Deciphering the multi-organ anti-fibrotic mechanisms of pirfenidone and nintedanib via network pharmacology
{{output}}
Background: Fibrosis is a systemic disorder driven by inflammation, immune imbalance, and extracellular matrix remodeling. Pirfenidone (PFD) and nintedanib (NTB), approved for idiopathic pulmonary fibrosis, may exert broader anti... ...
